ep adj dilut ep
valu usd unless otherwis note
becton dickinson compani
model updat ahead hq visit
view believ manag abil sustain organ
top-line growth execut bard cost/revenu synergi
key share perform hope gain addit
comfort topic today hq visit
comfort higher end impli
ep guidanc report better expect
sale growth y/i compar constant currenc basi
legaci bard revenu grow strong y/i
underli basi top-line growth includ bard
manag updat guidanc impli y/i growth
 bard cost synergi bard total cogs/
oper expens worth note achiev cost
save first three full quarter post carefus deal close
carefus total cogs/oper expens bard cost
synergi guidanc appear reason
rais estim rais revenu estim
y/i underli constant currenc
basi due solid result stronger expect flu season
favor fx also slightli rais cash ep estim
y/i updat revenu estim
y/i underli constant currenc basi
cash ep increas y/i price target remain
impli ebitda vs large-cap med-tech peer
group
look hq visit today may today
host investor visit hq franklin lake nj visit
includ meet vinc forlenza chairman ceo chri reidi
cfo tom polen presid pleas see sale rep would
like join us meet focus follow
topic sustain bard top-line growth addit detail
cost synergi target driver manag
oper margin target includ gore royalti health
compani product pipelin impact recent leadership chang
capit deploy goal next sever year abil
off-set gore royalti end part way
progress train rep cross-sel product move
piec guidanc fx raw materi price tax debt paydown etc
thought potenti futur expans amazon
dissemin may produc may price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
becton dickinson compani
expect perform line peers/sector
believ compani solid outlook larg reflect
acquisit add complementari product portfolio
medic busi posit global
leader medic manag patient safeti
solut expans market like infus
pump autom dispens infect prevent
addit see potenti revenu synergi
carefus deal strong intern presenc
particularli emerg market total sale
emerg market note time
acquisit carefus sale
portfolio limit overlap bard deal give
multi-year cost-cut opportun access bard
temperatur manag product biosurgeri home
care expect bard transact increas
ep growth trajectori mid-teen y/i appear
reason us also expect deal gener
annual pre-tax cost synergi
revenu synergi begin target
annual pre-tax cost synergi assum
reduct bard total cog oper expens vs
carefus
stock perform execut bard
revenue/cost synergi manag continu expect
low-single-digit ep accret bard also
reiter high-single-digit ep accret target
bard line model assum
cost synergi
assum cost synergi weight
heavili toward sg vs cog particularli
near term execut cost synergi crucial
manag guidanc assum annual
oper margin expans separ
potenti upsid may aris tax synergi well
revenu synergi latter could begin
exhibit becton dickinson compani
bloomberg capit market estim upside/downside/target
base case price target base
pro-forma ebitda estim includ bard
multipl larg in-line large-cap md peer group
base case scenario model organ top-lin
growth rang combin compani
bard scenario assum achiev
synergi bard bard organ top-
line growth rang also assum
stand-alone organ top-lin growth
bottom line model ep growth low-to-mid teen y/
upsid scenario assum share could trade
high next month upsid scenario
model organ top-lin growth includ bard
scenario assum achiev synergi
bard bard organ top-lin growth
rang also assum stand-alone organ
top-lin growth bottom line model
ep growth high-teen y/i includ bard
downsid scenario assum share could trade
low next month model organ
top-lin growth rang includ bard
scenario assum meet cost
synergi target rang bard bard organ top-lin
growth slow rang assum revenu
tax synergi bard downsid scenario
bottom line model ep growth double-digit y/i
becton dickinson compani
price target base pro-forma ebitda estim
combin compani bard target ev/ebitda multipl larg line
larg cap md peer group averag expect post strong top-
bottom-lin growth low-to-mid teen y/i next sever year
high leverag post bard deal pro-forma leverag price target
support sector perform rate
risk rate price target
delay and/or declin govern fund and/or capit spend increas competit
compani key market particularli diagnost fluctuat foreign currenc
failur integr acquisit unforeseen chang reimburs practic outcom
on-going lawsuit volatil emerg market unforeseen difficulti implement
compani erp system
becton dickinson co bd lead global supplier safety-engin product
inject infus therapi sampl collect surgeri sharp dispos bd also global
leader clinic flow cytometri strong global presenc microbiolog molecular
test cytolog complet acquisit carefus mid march
acquisit bard late decemb
becton dickinson compani
net incom applic common sharehold
becton dickinson compani
